Dr Reddy’s Laboratories Q4FY25 results: Dr Reddy’s Laboratories, the country’s leading India-based pharmaceutical company, released its March quarter performance on Friday, May 9, reporting a 22% year-on-year jump in consolidated net profit to ₹1,594 crore, beating Street estimates of ₹1,491 crore.
Revenue also exceeded estimates, coming in at ₹8,506 crore compared to ₹7,083 crore in the same period last year, marking a growth of 20%.
On the operating front, EBITDA came in at ₹2,975 crore, marking a 58.9% improvement compared to ₹1,872 crore in Q4FY23, while margins expanded by 510 basis points to reach 29.1%. In the same quarter of the previous fiscal year, the company had reported a margin of 24%.